Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Varamini, Pegah ^a   Mansfeld, Friederike M ^a   Blanchfield, Joanne T ^a   Wyse, Bruce D ^a   Smith, Maree T ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINODECANOIC ACID; 2,6 DIMETHYLTYROSINE; AMINO ACID DERIVATIVE; DECANOIC ACID DERIVATIVE; ENDOMORPHIN 1; ENDORPHIN DERIVATIVE; LIPO ENDOMORPHIN 1 DERIVATIVE; LIPOAMINO ACID MODIFIED DERIVATIVE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALOXONE; TYROSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC DISEASE; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE; DRUG MECHANISM; DRUG STABILITY; DRUG TOLERANCE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PROTEIN MODIFICATION; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; SINGLE DRUG DOSE; TREATMENT DURATION;

ANALGESICS; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CONSTIPATION; DRUG STABILITY; DRUG TOLERANCE; HUMANS; LIPID METABOLISM; MALE; NALOXONE; NEURALGIA; OLIGOPEPTIDES; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865095335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041909     Document Type: Article

References (42)

1. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, et al. (2008) Opioid Complications and Side Effects. Pain Physician 11: S105-S120.
2. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, et al. (2008) Neuropathic pain- Redefinition and a grading system for clinical and research purposes. Neurology 70: 1630-1635.
3. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, et al. (2007) Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 132: 237-251.
4. Gelman PL, Herrera NEG, Ortega MEM, Romero LP, Santillan CT, et al. (2010) Endomorphin peptides: pharmacological and functional implications of these opioid peptides in the brain of mammals. Part one. Salud Mental 33: 179-196.
5. Zadina JE, Hackler L, Ge L-J, Kastin AJ, (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386: 499-502.
6. Gentilucci L, (2004) New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr Top Med Chem 4: 19-38.
7. Horvath G, (2000) Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous μ-opioid receptor agonists. Pharmacol Ther 88: 437-463.
8. Przewlocki R, Przewlocka B, (2001) Opioids in chronic pain. Eur J Pharmacol 429: 79-91.
9. Goldberg IE, Rossi GC, Letchworth SR, Mathis JP, Ryan-Moro J, et al. (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286: 1007-1013.
10. Soignier RD, Vaccarino AL, Brennan AM, Kastin AJ, Zadina JE, (2000) Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice. Life Sci 67: 907-912.
11. Jinsmaa Y, Marczak E, Fujita Y, Shiotani K, Miyazaki A, et al. (2006) Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1]endomorphin-1. Pharmacol Biochem Behav 84: 252-258.
12. Spampinato S, Qasem AR, Calienni M, Murari G, Gentilucci L, et al. (2003) Antinociception by a peripherally administered novel endomorphin-1 analogue containing beta-proline. Eur J Pharmacol 469: 89-95.
13. Perlikowska R, do-Rego JC, Cravezic A, Fichna J, Wyrebska A, et al. (2010) Synthesis and biological evaluation of cyclic endomorphin-2 analogs. Peptides 31: 339-345.
14. Gao Y, Liu X, Wei J, Zhu B, Chen Q, et al. (2005) Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett 15: 1847-1850.
15. Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, et al. (2008) Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 16: 6286-6296.
16. Toth I, Hughes RA, Munday MR, Murphy CA, Mascagni P, et al. (1991) Lipidic peptides. II. Synthesis, activity and transport of anti-inflammatory benzoquinolizine-lipidic peptide conjugates. Int J Pharm 68: 191-198.
17. Blanchfield J, Toth I, (2004) Lipid, sugar and liposaccharide based delivery systems 2. Curr Med Chem 11: 2375-2382.
18. Li TY, Fujita Y, Tsuda Y, Miyazaki A, Ambo A, et al. (2005) Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J Med Chem 48: 586-592.
19. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, et al. (2005) The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21: 1-26.
20. Harrison C, McNulty S, Smart D, Rowbotham DJ, Grandy DK, et al. (1999) The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant μ-opioid receptors and SH-SY5Y cells. Br J Pharmacol 128: 472-478.
21. Bennett GJ, Chung JM, Honore M, Seltzer Z, (2003) Models of neuropathic pain in the rat. Curr Protoc Neurosci Chapter 9: Unit 9-14.
22. Emese C, Gabriella J, Geza T, Ildiko D, Gyorgy B, et al. (2001) Antinociceptive effect of continuous intrathecal administration of endomorphin-1. Pain 94: 31-38.
23. Allt G, Lawrenson JG, (2000) The blood-nerve barrier: enzymes, transporters and receptors-a comparison with the blood-brain barrier. Brain Res Bull 52: 1-12.
24. Egleton RD, Abbruscato TJ, Thomas SA, Davis TP, (1998) Transport of opioid peptides into the central nervous system. J Pharm Sci 87: 1433-1439.
25. Banks WA, Audus KL, Davis TP, (1992) Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 13: 1289-1294.
26. Banks WA, Kastin AJ, (1985) Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 15: 287-292.
27. Rapoport SI, Klee WA, Pettigrew KD, Ohno K, (1980) Entry of opioid peptides into the central nervous system. Science 207: 84-86.
28. Smetanova L, Stetinova V, Svoboda Z, Kvetina J, (2011) Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver. Acta Medica (Hradec Kralove) 54: 3-8.
29. Thiel-Demby VE, Humphreys JE, St John Williams LA, Ellens HM, Shah N, et al. (2009) Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Mol Pharm 6: 11-18.
30. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, et al. (2002) Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res 19: 976-981.
31. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, et al. (2005) In vitro models for the blood-brain barrier. Toxicol In Vitro 19: 299-334.
32. Leon SS, Wu-Pong S,Yu ABC (2005) Applied biopharmaceutics & pharmacokinetics. New YorkMcGraw-Hill.
33. Dey PK, Feldberg W, (1976) Analgesia produced by morphine when acting from the liquor space. Br J Pharmacol 58: 383-393.
34. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, et al. (2007) Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132: 289-300.
35. Idänpään-Heikkilä JJ, Guilbaud G, Kayser V, (1997) Prevention of Tolerance to the Antinociceptive Effects of Systemic Morphine by a Selective Cholecystokinin-B Receptor Antagonist in a Rat Model of Peripheral Neuropathy. J Pharmacol Exp Ther 282: 1366-1372.
36. Soignier RD, Vaccarino AL, Fanti KA, Wilson AM, Zadina JE, (2004) Analgesic tolerance and cross-tolerance to i.c.v. endomorphin-1, endomorphin-2, and morphine in mice. Neurosci Lett 366: 211-214.
37. Labuz D, Przewlocki R, Przewlocka B, (2002) Cross-tolerance between the different mu-opioid receptor agonists endomorphin-1, endomorphin-2 and morphine at the spinal level in the rat. Neurosci Lett 334: 127-130.
38. Hung KC, Wu HE, Mizoguchi H, Tseng LF, (2002) Acute antinociceptive tolerance and unidirectional cross-tolerance to endomorphin-1 and endomorphin-2 given intraventricularly in the rat. Eur J Pharmacol 448: 169-174.
39. Tsuji A, (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. Neurorx 2: 54-62.
40. Alewood P, Alewood D, Miranda L, Love S, Meutermans W, et al. (1997) Rapid in situ neutralization protocols for Boc and Fmoc solid-phase chemistries. In: Gregg BF, editor. Methods Enzymol: Academic Press. pp. 14-29.
41. Vojkovsky T, (1995) Detection of secondary-amines on solid-phase. Pept Res 8: 236-237.
42. Sarin VK, Kent SBH, Tam JP, Merrifield RB, (1981) Quantitative monitoring of solid-phase peptide synthesis by the ninhydrin reaction. Anal Biochem 117: 147-157.